Acute myeloblastic leukemia in patients with multiple myeloma.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to D Apel.
Explore the source record for details and available documents.
Thirty patients with acute non-lymphoblastic leukaemia were treated. They were randomly assigned to treatment according to programme AR (14 patients) and RAMP (16 patients). The groups were comparable for age and haematological state. Complete remission was obtained in 7 patients out of 14 treated by the AR programme and 6 out of 16 treated by the RAMP programme. The median duration of complete remission is as yet 15 weeks and 16 weeks respectively. The toxic side effects during treatment by the AR programme was statistically significantly higher than in the treatment by the RAMP programme. In the first group 42.8% of early deaths occurred, while in the second group 6.2% patients died early.
On the basis of standardized protocols of the therapeutic results of acute non-lymphoblastic leukaemias in adults sent to the Institute of Haematology in Warsaw from 8 haematological centres in Poland it was demonstrated that complete remission occurred in 34.4% of patients (129 out of 375 cases). The mean survival time of the patients treated intensively according to programmes I, II, III and IV 8.6 months, those of patients with complete remission - 13.5 months, patients without complete remission - 3.7 months. The most frequent cause of death (82.5%) were infections and/or haemarrhagic diathesis.